Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Holding RVMD?
Track your performance easily
RVMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.44 - $48.61
Previous Close$47.34
Volume1.44M
Average Volume (3M)1.31M
Market Cap
$7.91B
Enterprise Value$6.40B
Total Cash (Recent Filing)$1.59B
Total Debt (Recent Filing)$87.41M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 04, 2024EPS Estimate
-$0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.65
Shares Outstanding167,038,943
10 Day Avg. Volume1,014,740
30 Day Avg. Volume1,311,667
Standard Deviation0.17
R-Squared0.21
Alpha0.00049
Financial Highlights & Ratios
Price to Book (P/B)4.93
Price to Sales (P/S)10652.67
Price to Cash Flow (P/CF)-15.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.63K
Enterprise Value/Gross Profit553.05
Enterprise Value/Ebitda-12.86
Forecast
1Y Price Target
$57.33Price Target Upside15.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Revolution Medicines News
PremiumCompany Announcements
Revolution Medicines Appoints Frank Clyburn to Expanded Board
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsEncouraging clinical data from the innovative RAS(ON) platform, coupled with the large addressable population of RAS-dependent cancers, support a positive long-term outlook for RVMD.
Financial StrengthRevolution Medicines is considered one of the best-financed development-stage companies in the precision oncology domain, ending 2Q24 with roughly $1.59B in cash and cash equivalents, providing an operational runway into 2027.
Pipeline ProgressRVMD announced continued pipeline progress with its clinical-stage RAS ON inhibitors, with promising updates to the RMC-6236 Phase I data in pancreatic ductal adenocarcinoma, setting the stage for the pivotal Phase III RASolute 302 trial.
Bears Say
Clinical TrialsA failure of RMC-9805 could drive a 15% downside to the valuation.
Regulatory And Sales RisksRisks include, but are not limited to: clinical setbacks with RMC-4630; inability to secure timely regulatory approval for RMC-4630; poorer-than-anticipated RMC-4630 sales performance; failures with other pipeline candidates, notably the RAS(ON) inhibitors; and possible long-term dilution risk.
Side Effects And EfficacyEmerging side effect issues such as large intestine perforation and lack of durable responses in PDAC could impact progression-free survival.
---
Ownership Overview
6.24% Insiders
27.11% Mutual Funds
0.04% Other Institutional Investors
51.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $15.44 and its highest was $48.61 in the past 12 months.
What is Revolution Medicines’s market cap?
Currently, no data Available
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Nov 04, 2024 which is in 18 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Aug 07, 2024. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.775 by -$0.035.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -$0.89.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 167,038,940 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.775. Following the earnings report the stock price went down -0.686%.
Which hedge fund is a major shareholder of Revolution Medicines?
Among the largest hedge funds holding Revolution Medicines’s share is Farallon Capital Management, L.L.C.. It holds Revolution Medicines’s shares valued at 379M.
---
Revolution Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.33 (15.19% Upside)
$57.33 (15.19% Upside)
Blogger Sentiment
Neutral
RVMD Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.05%
12-Months-Change
Fundamentals
Return on Equity
-40.73%
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
RVMD Earnings Call
Q2 2024
0:00 / 0:00
---
RVMD Stock 12 Month Forecast
Average Price Target
$57.33
▲(15.19% Upside)
Technical Analysis
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+40.08%
reiterated a buy rating 2 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +40.08% per trade.
---